Keros Therapeutics, Inc.

Healthcare

NASDAQ:KROS · NASDAQ Global Market

Market Cap $340.78M Beta 0.96 P/E (TTM) -4.6

$10.65 +1.20%

+$0.13 today

52W Low $9.69High $22.55

Vol 0.40M · Avg 0.36M

EPS (TTM) -$2.29Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-22.60%

Period High

$21.84

Period Low

$9.91

Latest

$10.65

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

MoonLake Immunotherapeutics

NASDAQ:MLTX

$1.42B

Absci Corporation

NASDAQ:ABSI

$1.14B

Ventyx Biosciences, Inc.

VTYX

$1.00B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$995.63M

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

$804.20M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

$609.46M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

$472.02M

REGENXBIO Inc.

NASDAQ:RGNX

$419.01M

Verastem, Inc.

NASDAQ:VSTM

$289.73M

Niagen Bioscience Inc

NASDAQ:NAGE

$277.56M

What is the latest KROS filing?

The latest filing shown is 4 dated Jun 17, 2026.

How many recent filings does KROS have?

Intrinsic Alpha currently shows 20 recent filings for KROS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.